David H. Adams

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

National Outcomes in Acute Aortic Dissection: Influence of Surgeon and Institutional Volume on Operative Mortality

Joanna Chikwe, Paul Cavallaro, Shinobu Itagaki et al. · The Annals of Thoracic Surgery · 2013 · 267 citations

Medicine, Perioperative Medicine, Surgery +15

Relation of Mitral Valve Surgery Volume to Repair Rate, Durability, and Survival

Joanna Chikwe, Nana Toyoda, Anelechi Anyanwu et al. · Journal of the American College of Cardiology · 2017 · 256 citations · Full text

Medicine, Cardiology, Surgery +12

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 214 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

Hong Liu‐Seifert, David H. Adams, Bruce J. Kinon · BMC Medicine · 2005 · 152 citations · Full text

Pharmacy, Pharmacotherapy, Psychiatry +16